When the analysis was conducted, 26 states plus Washington, D.C. had expanded Medicaid. That created an opportunity to look at the impact of Medicaid expansion on the number of Medicaid patients with newly identified diabetes among enrollees (age 19–64) who had laboratory testing through Quest Diagnostics.
Researchers, which compared the number of newly identified diabetics in 2014 to the number of newly identified diabetics in 2013, found that the number of Medicaid patients with newly identified diabetes surged 23 percent in states that expanded Medicaid, but increased by only 0.4 percent in states that did not.
Researchers also found that Medicaid patients in the expansion states had lower mean hemoglobin A1c levels than Medicaid patients in nonexpansion states. Researchers said this supports their observation that the newly identified patients with diabetes in the expansion states are more likely at an earlier state of their disease than within the nonexpansion states.
“We postulate that these Medicaid patients with newly identified diabetes will experience better management of their disease than if diagnoses had been made later,” the researchers wrote. “This could be anticipated to lead to fewer long-term complications.”
More articles on infection control & clinical quality:
New national database offers benchmarks for total hip, knee joint replacements
Norovirus symptoms last roughly 44 hours, regardless of outside factors
Care coordination and technology: The keys to improving post-discharge care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
